All In MedTech

FDA Clearance Tracker · P230013-S027

EVOQUE Tricuspid Valve Replacement System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 16, 2026

Approved

Time to decision

180 days

Received Mar 20, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P230013-S027
Device name
EVOQUE Tricuspid Valve Replacement System
Applicant location
Irvine, CA
Received
Mar 20, 2026
Decided
Sep 16, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P230013

Device type

Device class
Class III

Every decision under product code NPW

FDA's approval statement

As written in FDA's record.

Approval for various modifications to the Instructions for Use, including the addition of internal jugular venous access and revision of the sizing table.

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.